Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:HUMA 12 November 2025

Humacyte (HUMA) Q3 2025: Symvess Sales Surge; IND Filed for CABG as Dialysis Data Advance — Nov 12, 2025

Humacyte (HUMA) Q3 2025: Symvess Sales Surge; IND Filed for CABG as Dialysis Data Advance — Nov 12, 2025

Humacyte reported Q3 revenue of $753,000, with $703,000 from Symvess sales, and a net loss of $17.5 million (GAAP EPS −$0.11). The company said 25 Value Analysis Committee approvals now cover 92 U.S. hospitals, with 16 hospitals ordering Symvess. Positive two-year Phase 3 dialysis trial results were presented, and an IND was submitted for a coronary bypass graft study in 2026.
12 November 2025
··

Stock Market Today

  • Meta Unveils AI Safety Tool to Boost User Engagement and Ad Revenues
    March 20, 2026, 1:13 PM EDT. Meta Platforms is launching a new AI-driven support assistant across Facebook and Instagram to enhance safety and security features. The tool aims to resolve user issues swiftly, handling scams, impersonation, privacy settings, and more within five seconds. Meta's AI focus, powered by data from over 3.58 billion daily users, is expected to increase user engagement and advertising revenues, which represent 98.6% of its app family income. This move comes amid intense competition in digital advertising from Alphabet and Amazon. Meta projects first-quarter 2026 revenues between $53.5 billion and $56.5 billion, showing potential growth of over 30% year-on-year. Alphabet's Google advertising revenue rose 13.6% in late 2025, underscoring the competitive pressure in AI-enhanced ad markets.
Go toTop